Published in J Burn Care Res on July 09, 2012
C1-Inhibitor protects from focal brain trauma in a cortical cryolesion mice model by reducing thrombo-inflammation. Front Cell Neurosci (2014) 0.90
Complement activation and inhibition in wound healing. Clin Dev Immunol (2012) 0.85
Experimental full-thickness burns induced by CO2 laser. Lasers Med Sci (2014) 0.76
Current concepts on burn wound conversion-A review of recent advances in understanding the secondary progressions of burns. Burns (2016) 0.76
Complement Activation and STAT4 Expression Are Associated with Early Inflammation in Diabetic Wounds. PLoS One (2017) 0.75
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
The patient and observer scar assessment scale: a reliable and feasible tool for scar evaluation. Plast Reconstr Surg (2004) 3.14
Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation (2007) 3.12
Myocardial structure and function differ in systolic and diastolic heart failure. Circulation (2006) 3.11
Effectiveness of Autologous Fat Grafting in Adherent Scars: Results Obtained by a Comprehensive Scar Evaluation Protocol. Plast Reconstr Surg (2017) 3.04
Clinical effectiveness of dermal substitution in burns by topical negative pressure: a multicenter randomized controlled trial. Wound Repair Regen (2012) 2.78
Potential cellular and molecular causes of hypertrophic scar formation. Burns (2008) 2.39
PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol (2012) 2.39
Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation (2012) 2.14
Morphometry of dermal collagen orientation by Fourier analysis is superior to multi-observer assessment. J Pathol (2002) 1.98
Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir. Eur Heart J (2013) 1.83
Prevention and curative management of hypertrophic scar formation. Burns (2008) 1.63
C-reactive protein and the risk of cardiovascular mortality. Am J Med (2003) 1.62
Diaphragm muscle fiber weakness and ubiquitin-proteasome activation in critically ill patients. Am J Respir Crit Care Med (2015) 1.52
Costs of burn care: a systematic review. Wound Repair Regen (2014) 1.49
Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res (2012) 1.49
Topical silicone gel versus placebo in promoting the maturation of burn scars: a randomized controlled trial. Plast Reconstr Surg (2010) 1.48
A tick mannose-binding lectin inhibitor interferes with the vertebrate complement cascade to enhance transmission of the lyme disease agent. Cell Host Microbe (2011) 1.44
Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Ann Neurol (2006) 1.40
"Reply to: Effectiveness of autologous fat grafting in adherent scars: results obtained by a comprehensive scar evaluation protocol". Plast Reconstr Surg (2017) 1.38
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis (2012) 1.35
Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension. AJR Am J Roentgenol (2007) 1.28
Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation (2011) 1.22
A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys (2006) 1.22
Scar assessment tools: implications for current research. Plast Reconstr Surg (2002) 1.21
Colour evaluation in scars: tristimulus colorimeter, narrow-band simple reflectance meter or subjective evaluation? Burns (2004) 1.19
Differential effect of drug interference in immunogenicity assays. J Immunol Methods (2011) 1.17
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods (2010) 1.17
Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. Matrix Biol (2004) 1.16
Biological background of dermal substitutes. Burns (2009) 1.15
Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14
Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol (2012) 1.14
C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med (2002) 1.14
Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis. Wound Repair Regen (2009) 1.13
Collagen morphology in human skin and scar tissue: no adaptations in response to mechanical loading at joints. Burns (2003) 1.11
Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage. Eur Heart J (2013) 1.11
Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Eur Heart J (2009) 1.11
Comparison between human fetal and adult skin. Arch Dermatol Res (2009) 1.10
Allogeneic fibroblasts in dermal substitutes induce inflammation and scar formation. Wound Repair Regen (2002) 1.06
Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Basic Res Cardiol (2011) 1.05
Skin elasticity meter or subjective evaluation in scars: a reliability assessment. Burns (2004) 1.05
Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease. PLoS One (2009) 1.05
International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis (2006) 1.04
Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: a prospective nested case-control study. Crit Care Med (2012) 1.04
Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta (2004) 1.02
More severe cellular phenotype in human idiopathic dilated cardiomyopathy compared to ischemic heart disease. J Muscle Res Cell Motil (2010) 1.02
Differential response of human adipose tissue-derived mesenchymal stem cells, dermal fibroblasts, and keratinocytes to burn wound exudates: potential role of skin-specific chemokine CCL27. Tissue Eng Part A (2013) 1.01
Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Ann N Y Acad Sci (2005) 1.01
Dermal substitution in acute burns and reconstructive surgery: a 12-year follow-up. Plast Reconstr Surg (2010) 1.00
T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. Circ Cardiovasc Imaging (2012) 0.99
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis (2013) 0.99
Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol (2010) 0.98
CD44 is protective during hyperoxia-induced lung injury. Am J Respir Cell Mol Biol (2010) 0.98
Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum (2008) 0.97
Adaptation of the dermal collagen structure of human skin and scar tissue in response to stretch: an experimental study. Wound Repair Regen (2012) 0.97
IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol (2012) 0.96
Rasch analysis of the Patient and Observer Scar Assessment Scale (POSAS) in burn scars. Qual Life Res (2011) 0.95
Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. Arterioscler Thromb Vasc Biol (2011) 0.95
Culture of keratinocytes for transplantation without the need of feeder layer cells. Cell Transplant (2007) 0.95
New dermal substitutes. Wound Repair Regen (2011) 0.95
C-reactive protein activates complement in infarcted human myocardium. Am J Pathol (2003) 0.94
Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res (2013) 0.94
TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol (2006) 0.94
C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood (2013) 0.94
Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods (2011) 0.94
Wound healing in a fetal, adult, and scar tissue model: a comparative study. Wound Repair Regen (2010) 0.93
Blood plasma inflammation markers during epileptogenesis in post-status epilepticus rat model for temporal lobe epilepsy. Epilepsia (2013) 0.92
Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res (2003) 0.92
Inhibition of Rho-ROCK signaling induces apoptotic and non-apoptotic PS exposure in cardiomyocytes via inhibition of flippase. J Mol Cell Cardiol (2010) 0.91
Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. Wound Repair Regen (2011) 0.90
Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheumatol (2014) 0.90
Collagen bundle morphometry in skin and scar tissue: a novel distance mapping method provides superior measurements compared to Fourier analysis. J Microsc (2011) 0.90
Enhanced myofilament responsiveness upon β-adrenergic stimulation in post-infarct remodeled myocardium. J Mol Cell Cardiol (2010) 0.90
Monomeric C-reactive protein modulates classic complement activation on necrotic cells. FASEB J (2011) 0.90
N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis (2004) 0.89
Intravenous clusterin administration reduces myocardial infarct size in rats. Eur J Clin Invest (2010) 0.89
Mechanical ventilation during experimental sepsis increases deposition of advanced glycation end products and myocardial inflammation. Crit Care (2009) 0.89
Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis. Cancer Lett (2005) 0.89
Activation of factor VII-activating protease in human inflammation: a sensor for cell death. Crit Care (2011) 0.88
Pressure-diameter relationship in the human greater saphenous vein. Ann Thorac Surg (2003) 0.87
Burns to the head and neck: Epidemiology and predictors of surgery. Burns (2013) 0.87
Collagen cross-linking by adipose-derived mesenchymal stromal cells and scar-derived mesenchymal cells: Are mesenchymal stromal cells involved in scar formation? Wound Repair Regen (2009) 0.87
Acute inflammation is persistent locally in burn wounds: a pivotal role for complement and C-reactive protein. J Burn Care Res (2009) 0.87
The bacteria binding glycoprotein salivary agglutinin (SAG/gp340) activates complement via the lectin pathway. Mol Immunol (2011) 0.87
Novel COL4A1 mutations cause cerebral small vessel disease by haploinsufficiency. Hum Mol Genet (2012) 0.87
Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction? Cardiovasc Hematol Disord Drug Targets (2006) 0.87